CDT
CDT Equity Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CDT
this stock
CDT Equity Inc.
|
$2.15M | -98.6% | — | — | 0.8% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -32.3K sh
- Top holder
- Tower Research Capital LL…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CDT | -21.1% | -43.0% | -98.7% | -21.1% | -98.6% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -22.0% | -44.4% | -106.3% | -21.2% | -108.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.